Genetic Testing for Opioid Use Disorder Heads to FDA Advisors

(MedPage Today) -- On Thursday, members of the FDA's Clinical Chemistry and Clinical Toxicology Devices Advisory Committee will meet to discuss AvertD, a prescription genetic risk assessment tool for opioid use disorder (OUD).
AvertD detects the...